
Xiao-Hui Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7298157/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. Platelets, 2022, 33, 82-88.	2.3	17
2	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia, 2022, 36, 267-270.	7.2	14
3	Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. British Journal of Haematology, 2022, 196, 735-742.	2.5	3
4	Dose tapering to withdrawal stage and longâ€ŧerm efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open″abel extension study. Journal of Thrombosis and Haemostasis, 2022, 20, 716-728.	3.8	6
5	Donor activating killer cell immunoglobulinâ€like receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2022, 196, 1007-1017.	2.5	4
6	Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Frontiers in Immunology, 2022, 13, 757002.	4.8	13
7	Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation. International Journal of Laboratory Hematology, 2022, 44, 510-517.	1.3	3
8	Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplantation, 2022,	2.4	5
9	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2022, 22, 11.	2.6	2
10	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft- <i>versus</i> -host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Therapeutic Advances in Hematology, 2022, 13, 204062072110728.	2.5	8
11	Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation. JCI Insight, 2022, 7, .	5.0	8
12	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cellular and Molecular Immunology, 2022, 19, 482-491.	10.5	15
13	Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study. Science Bulletin, 2022, 67, 963-970.	9.0	15
14	Basiliximab for steroidâ€refractory acute graftâ€versusâ€host disease: A realâ€world analysis. American Journal of Hematology, 2022, 97, 458-469.	4.1	19
15	Single-cell Transcriptomic Analysis Reveals the Cellular Heterogeneity of Mesenchymal Stem Cells. Genomics, Proteomics and Bioinformatics, 2022, 20, 70-86.	6.9	27
16	Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis Bâ€related cirrhosis: Multicentre realâ€world observational study. Journal of Viral Hepatitis, 2022, 29, 306-316.	2.0	4
17	Recipient and donor PTX3 rs2305619 polymorphisms increase the susceptibility to invasive fungal disease following haploidentical stem cell transplantation: a prospective study. BMC Infectious Diseases, 2022, 22, 292.	2.9	2
18	Adoptive therapy with <scp>cytomegalovirus</scp> â€specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy. American Journal of Hematology, 2022, 97, 762-769.	4.1	14

#	Article	IF	CITATIONS
19	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2022, 12, 862526.	3.9	7
20	Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. Journal of Hematology and Oncology, 2022, 15, 22.	17.0	24
21	The glycolytic enzyme PFKFB3 determines bone marrow endothelial progenitor cell damage after chemotherapy and irradiation. Haematologica, 2022, 107, 2365-2380.	3.5	8
22	Flow Characteristics of the Liquid Film During Centrifugal Granulation of Liquid Slag on the Surface of Rotary Cup. Journal of Sustainable Metallurgy, 2022, 8, 632-645.	2.3	2
23	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.8	5
24	Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes. Journal of Translational Medicine, 2022, 20, 144.	4.4	3
25	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic Advances in Hematology, 2022, 13, 204062072210952.	2.5	5
26	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	4.8	3
27	Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial. BMC Medicine, 2022, 20, 140.	5.5	8
28	The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia. Frontiers in Immunology, 2022, 13, .	4.8	4
29	A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Experimental Hematology and Oncology, 2022, 11, 25.	5.0	19
30	Combination of <i>KIT</i> and <i>FLT3â€</i> ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Hematological Oncology, 2022, 40, 724-733.	1.7	2
31	Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplantation, 2022, 57, 1204-1206.	2.4	5
32	CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clinical and Experimental Immunology, 2022, 208, 332-339.	2.6	6
33	Clinical practice of precision medicine in lymphoma. Clinical and Translational Discovery, 2022, 2, .	0.5	0
34	An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood, 2022, 140, 516-520.	1.4	18
35	The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents. Pediatric Blood and Cancer, 2022, 69, .	1.5	1
36	Cell Softness Prevents Cytolytic T-cell Killing of Tumor-Repopulating Cells. Cancer Research, 2021, 81, 476-488.	0.9	54

#	Article	IF	CITATIONS
37	The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in <i>CBFB–MYH11</i> â€positive acute myeloid leukaemia indicates poor prognosis. British Journal of Haematology, 2021, 192, 265-271.	2.5	13
38	Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. Platelets, 2021, 32, 633-641.	2.3	6
39	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Annals of Hematology, 2021, 100, 169-180.	1.8	14
40	Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia, 2021, 35, 1563-1570.	7.2	49
41	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clinical Transplantation, 2021, 35, e14160.	1.6	12
42	Clodronate-liposomes aggravate irradiation-induced myelosuppression by promoting myeloid differentiation. International Journal of Radiation Biology, 2021, 97, 240-248.	1.8	2
43	Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia. Science China Life Sciences, 2021, 64, 766-783.	4.9	10
44	High <i>PRDM16</i> expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese center. Leukemia and Lymphoma, 2021, 62, 185-193.	1.3	3
45	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. Annals of Hematology, 2021, 100, 799-808.	1.8	2
46	Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graftâ€versusâ€host disease. Transplant Infectious Disease, 2021, 23, e13544.	1.7	5
47	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology, 2021, 100, 505-516.	1.8	4
48	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Annals of Hematology, 2021, 100, 1203-1212.	1.8	10
49	Efficacy of acupuncture for sciatica: study protocol for a randomized controlled pilot trial. Trials, 2021, 22, 34.	1.6	3
50	Preâ€transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Communications, 2021, 41, 333-344.	9.2	5
51	Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. Frontiers in Oncology, 2021, 11, 639502.	2.8	4
52	A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Journal of Hematology and Oncology, 2021, 14, 37.	17.0	33
53	HCMV modulates câ€Mpl/IEXâ€1 pathwayâ€mediated megakaryo/thrombopoiesis via PDGFRα and αvβ3 recepto after alloâ€HSCT. Journal of Cellular Physiology, 2021, 236, 6726-6741.	ors 4.1	1
54	Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. BMC Cancer, 2021, 21, 292.	2.6	5

#	Article	IF	CITATIONS
55	A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chinese Medical Journal, 2021, 134, 1199-1208.	2.3	3
56	G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. Frontiers in Oncology, 2021, 11, 631625.	2.8	8
57	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. Transplantation and Cellular Therapy, 2021, 27, 253.e1-253.e9.	1.2	1
58	The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. Frontiers in Oncology, 2021, 11, 632532.	2.8	9
59	Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. American Journal of Hematology, 2021, 96, 561-570.	4.1	5
60	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2021, 100, 1267-1281.	1.8	3
61	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2097-2107.	2.4	9
62	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. Leukemia, 2021, 35, 3092-3100.	7.2	22
63	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 67.	6.2	9
64	Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis. Blood, 2021, 138, 1211-1224.	1.4	59
65	Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. Current Medical Science, 2021, 41, 443-453.	1.8	3
66	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. Frontiers in Medicine, 2021, 8, 604085.	2.6	13
67	M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. Signal Transduction and Targeted Therapy, 2021, 6, 234.	17.1	37
68	γδT Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation. Frontiers in Immunology, 2021, 12, 687961.	4.8	5
69	Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion. Frontiers of Medicine, 2021, 15, 728-739.	3.4	Ο
70	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. Bone Marrow Transplantation, 2021, 56, 2723-2731.	2.4	4
71	Improved function and balance in T cell modulation by endothelial cells in young people. Clinical and Experimental Immunology, 2021, 206, 196-207.	2.6	4
72	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. Frontiers in Oncology, 2021, 11, 706935.	2.8	3

#	Article	IF	CITATIONS
73	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 668.e1-668.e9.	1.2	3
74	Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplantation, 2021, 56, 2940-2947.	2.4	43
75	Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. Blood Advances, 2021, 5, 4910-4921.	5.2	4
76	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. American Journal of Hematology, 2021, 96, 1407-1419.	4.1	5
77	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. Frontiers in Immunology, 2021, 12, 749266.	4.8	12
78	The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. Journal of Hematology and Oncology, 2021, 14, 145.	17.0	124
79	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Advances, 2021, 5, 5479-5489.	5.2	6
80	All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematology,the, 2021, 8, e688-e699.	4.6	19
81	Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models. Bone Marrow Transplantation, 2021, 56, 1341-1351.	2.4	8
82	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. Annals of Hematology, 2021, 100, 555-562.	1.8	5
83	A modified conditioning regimen based on lowâ€dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity. Clinical Transplantation, 2021, , e14514.	1.6	3
84	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood, 2021, , .	1.4	10
85	Machine-Learning Model for Resistance/Relapse Prediction in Immune Thrombocytopenia Using Gut Microbiota and Function Signatures. Blood, 2021, 138, 18-18.	1.4	1
86	Treatment Outcome and Efficacy of Therapeutic Plasma Exchange for Transplant-Associated Thrombotic Microangiopathy in a Real-World Large Cohort Study. Blood, 2021, 138, 1013-1013.	1.4	0
87	All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP. Blood, 2021, 138, 15-15.	1.4	0
88	Detection of <i>CSRP2</i> Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL. Blood, 2021, 138, 3998-3998.	1.4	0
89	Mesenchymal Stromal Cells Plus Anti-CD25 Antibody and Calcineurin Inhibitors for Steroid-Resistant Acute Graft-Versus-Host Disease: A Multicenter, Randomized, Phase 3 Trial. Blood, 2021, 138, 260-260.	1.4	0
	Tagralimus Dlus High Daga Davamathagang Varsus High Daga Davamathagang Alang As First Ling		

Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line
Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET) Tj ETQq0 0 OrgBT /Overlock 10 Ti

#	Article	IF	CITATIONS
91	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Frontiers in Immunology, 2021, 12, 731435.	4.8	4
92	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology, 2021, 11, 773394.	2.8	8
93	Subspace-based domain adaptation for few-shot fault diagnosis. , 2021, , .		0
94	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)–specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 70, 1429-1437.	5.8	30
95	Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). Science China Life Sciences, 2020, 63, 571-581.	4.9	26
96	The Quantification of Minimal Residual Disease Pre―and Postâ€Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 75-87.	1.5	18
97	Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. Science China Life Sciences, 2020, 63, 138-147.	4.9	4
98	Improved survival after offspring donor transplant compared with older agedâ€matched siblings for older leukaemia patients. British Journal of Haematology, 2020, 189, 153-161.	2.5	8
99	Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 351-357.	2.0	20
100	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1171-1178.	2.0	8
101	Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as postâ€remission treatment for children with very highâ€risk philadelphia chromosome negative Bâ€cell acute lymphoblastic leukaemia in first complete remission. British lournal of Haematology, 2020, 188, 757-767.	2.5	17
102	Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2020, 22, 188-195.	2.8	4
103	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. Pediatric Transplantation, 2020, 24, e13864.	1.0	5
104	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2020, 22, 755-761.	0.7	33
105	Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. Scientific Reports, 2020, 10, 20148.	3.3	7
106	The incidence, risk factors, and outcomes of acute graftâ€vsâ€host disease in pediatric Tâ€cellâ€replete haploidentical hematopoietic stem cell transplantation. Pediatric Transplantation, 2020, 24, e13793.	1.0	1
107	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2659-2670.	1.8	13
108	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. Biology of Blood and Marrow Transplantation, 2020, 26, 1655-1662.	2.0	8

#	Article	IF	CITATIONS
109	Current and emerging treatments based on novel mechanisms for immune thrombocytopenia. Science China Life Sciences, 2020, 63, 1597-1599.	4.9	0
110	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Advances, 2020, 4, 5846-5857.	5.2	5
111	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. Journal of Hematology and Oncology, 2020, 13, 52.	17.0	13
112	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 2087-2097.	2.4	8
113	Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. Science China Life Sciences, 2020, 63, 1744-1754.	4.9	14
114	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplantation, 2020, 55, 2035-2042.	2.4	11
115	Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data. British Journal of Haematology, 2020, 191, 269-281.	2.5	5
116	miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. Molecular Therapy - Nucleic Acids, 2020, 20, 764-776.	5.1	28
117	Haploidenticalâ€versus identicalâ€sibling transplant for highâ€risk pediatric AML: A multiâ€center study. Cancer Communications, 2020, 40, 93-104.	9.2	20
118	CD8+CD161hi T cells are associated with acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1652-1654.	2.4	3
119	Monocyte subsets in bone marrow grafts may contribute to a low incidence of acute graftâ€vsâ€host disease for young donors. Journal of Cellular and Molecular Medicine, 2020, 24, 9204-9216.	3.6	2
120	Recent advances in CAR-T cell engineering. Journal of Hematology and Oncology, 2020, 13, 86.	17.0	192
121	Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation. Thrombosis Research, 2020, 194, 168-175.	1.7	2
122	Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1833-1843.	1.8	3
123	Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplantation, 2020, 55, 1068-1075.	2.4	9
124	Detection of measurable residual disease may better predict outcomes than mutations based on nextâ€generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. British Journal of Haematology, 2020, 190, 533-544.	2.5	14
125	Mutation topography and risk stratification for <i>de novo</i> acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (<i>NPM1</i>) mutation or Fmsâ€like tyrosine kinase 3 internal tandem duplication (<i>FLT3â€</i> ITD). British Journal of Haematology, 2020, 190, 274-283.	2.5	18
126	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, 67-78.	2.5	11

#	Article	IF	CITATIONS
127	Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. Science China Life Sciences, 2020, 63, 1261-1264.	4.9	8
128	Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. Science China Life Sciences, 2020, 63, 1552-1564.	4.9	12
129	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1203-1209.	2.0	9
130	Autophagy in endothelial cells regulates their haematopoiesis-supporting ability. EBioMedicine, 2020, 53, 102677.	6.1	13
131	Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Science Immunology, 2020, 5, .	11.9	314
132	Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study. Clinical Transplantation, 2020, 34, e13810.	1.6	16
133	Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1147-1160.	2.4	18
134	Incidence, Risk Factors, and Outcomes of Primary Prolonged Isolated Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, 1452-1458.	2.0	10
135	A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2649-2657.	1.8	2
136	Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2+T cells activities after hematopoietic transplantation for blood malignancies. , 2020, 8, e000208.		18
137	Prognostic factors and longâ€ŧerm followâ€up of basiliximab for steroidâ€refractory acute <scp>graftâ€versusâ€host disease</scp> : Updated experience from a largeâ€scale study. American Journal of Hematology, 2020, 95, 927-936.	4.1	32
138	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. Journal of Hematology and Oncology, 2020, 13, 27.	17.0	48
139	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Frontiers in Oncology, 2020, 10, 320.	2.8	17
140	Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 620891.	4.8	21
141	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. Annals of Hematology, 2020, 99, 1643-1653.	1.8	3
142	Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation. Medicine (United States), 2020, 99, e23569.	1.0	6
143	Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Clobulin in Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-20.	1.4	7
144	Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes. Blood, 2020, 136, 42-43.	1.4	0

#	Article	IF	CITATIONS
145	M2 Macrophages, but Not M1 Macrophages, Support Megakaryopoiesis Via up-Regulating PI3K-AKT Pathway. Blood, 2020, 136, 1-1.	1.4	Ο
146	PGE2 Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD. Blood, 2020, 136, 15-15.	1.4	1
147	M1 and M2 Macrophages Play Different Roles in the Pathogenesis of Acute Graft-Versus-Host Disease Post-Allotransplant By Modulating Immune Microenvironment. Blood, 2020, 136, 19-20.	1.4	0
148	Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 16-17.	1.4	0
149	Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR+ and αvβ3+ Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT. Blood, 2020, 136, 25-25.	1.4	0
150	Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia. Blood, 2020, 136, 4-5.	1.4	0
151	Different Subsets of Haematopoietic Cells and Immune Cells in Bone Marrow between Young and Old Donors. Blood, 2020, 136, 33-34.	1.4	0
152	Risk and Prognostic Factors for Intracranial Hemorrhage in Elderly Patients with Immune Thrombocytopenia. Blood, 2020, 136, 14-15.	1.4	0
153	Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. Science China Life Sciences, 2019, 62, 104-111.	4.9	6
154	The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplantation, 2019, 54, 567-577.	2.4	19
155	High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. Cancer Medicine, 2019, 8, 5459-5467.	2.8	7
156	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. Journal of Hematology and Oncology, 2019, 12, 88.	17.0	76
157	Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. Journal of Hematology and Oncology, 2019, 12, 87.	17.0	24
158	The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. Annals of Hematology, 2019, 98, 2551-2559.	1.8	8
159	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. Frontiers of Medicine, 2019, 13, 667-679.	3.4	2
160	Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1310-1318.	2.4	38
161	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. American Journal of Hematology, 2019, 94, 512-521.	4.1	51
162	All- <i>trans</i> retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement–interleukin-1β loop. Haematologica, 2019, 104, 1661-1675.	3.5	25

#	Article	IF	CITATIONS
163	Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. Bone Marrow Transplantation, 2019, 54, 1319-1326.	2.4	35
164	G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1419-1433.	2.4	40
165	Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 354-364.	3.4	8
166	FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplantation, 2019, 54, 1462-1470.	2.4	9
167	Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100Âdays after allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1877-1883.	1.8	20
168	Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e349-e358.	0.4	8
169	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1733-1742.	1.8	6
170	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1629-1636.	2.0	6
171	Early myeloid-derived suppressor cells (HLA-DRâ ^{~'} /lowCD33+CD16â ^{~'}) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. Journal of Hematology and Oncology, 2019, 12, 31.	17.0	35
172	Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1694-1700.	2.4	9
173	<i>S100A16</i> suppresses the growth and survival of leukaemia cellsÂand correlates with relapse and relapse free survival in adults with Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 836-851.	2.5	7
174	Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation. Engineering, 2019, 5, 150-155.	6.7	8
175	Reduced β2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. Science China Life Sciences, 2019, 62, 921-929.	4.9	2
176	Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 492-503.	3.4	5
177	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 1210-1217.	2.0	2
178	Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. Blood Advances, 2019, 3, 1416-1428.	5.2	18
179	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Advances, 2019, 3, 1303-1317.	5.2	43
180	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2019, 3, 4312-4325.	5.2	27

#	Article	IF	CITATIONS
181	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. Blood Advances, 2019, 3, 3406-3418.	5.2	8
182	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Science China Life Sciences, 2019, 62, 691-697.	4.9	16
183	A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets, 2019, 30, 994-1000.	2.3	10
184	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clinical Cancer Research, 2019, 25, 1737-1748.	7.0	26
185	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. British Journal of Haematology, 2019, 184, 788-796.	2.5	8
186	Developing role of B cells in the pathogenesis and treatment of chronic GVHD. British Journal of Haematology, 2019, 184, 323-336.	2.5	33
187	Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation. Immunotherapy, 2019, 11, 37-44.	2.0	6
188	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Letters, 2019, 442, 193-201.	7.2	12
189	Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. Bone Marrow Transplantation, 2019, 54, 1198-1207.	2.4	12
190	A multicenter, prospective evaluation of the Chinese Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation. Thrombosis Research, 2019, 173, 131-140.	1.7	22
191	Occurrence and Severity of Donor Lymphocyte Infusion–Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 912-920.	2.0	4
192	Comments on the article: †Donorâ€derived <scp>CD</scp> 19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation'― Response to Pan <i>etÂal</i> . British Journal of Haematology, 2019, 184, 882-883.	2.5	0
193	Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 238-249.	3.4	18
194	ATRA Could Correct the Defective S1P-Mediated Cytoskeletal Reorganization in Proplatelet Formation of ITP. Blood, 2019, 134, 218-218.	1.4	1
195	The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis. Blood, 2019, 134, 2616-2616.	1.4	0
196	Autophagy in Endothelial Cells Regulates Their Hematopoiesis Supporting Ability. Blood, 2019, 134, 4425-4425.	1.4	0
197	The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts. Transplant Immunology, 2018, 48, 55-59.	1.2	3
198	Nâ€acetyl‣â€cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia postâ€allotransplant. British Journal of Haematology, 2018, 180, 863-878.	2.5	22

#	Article	IF	CITATIONS
199	Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. Functional and Integrative Genomics, 2018, 18, 287-299.	3.5	15
200	Nâ€acetyl‣â€cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2018, 93, 931-942.	4.1	29
201	Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China. Scientific Reports, 2018, 8, 2479.	3.3	18
202	Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Annals of Hematology, 2018, 97, 967-975.	1.8	27
203	Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Annals of Hematology, 2018, 97, 641-654.	1.8	9
204	Inverse correlation of Vĺ2 ⁺ Tâ€cell recovery with <scp>EBV</scp> reactivation after haematopoietic stem cell transplantation. British Journal of Haematology, 2018, 180, 276-285.	2.5	23
205	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood, 2018, 131, 1219-1233.	1.4	40
206	Congenital hypofibrinogenemia in pregnancy. Blood Coagulation and Fibrinolysis, 2018, 29, 155-159.	1.0	20
207	Firstâ€line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy. Clinical Transplantation, 2018, 32, e13179.	1.6	29
208	Perianal Infections in the Phase before Engraftment after Allogeneic Hematopoietic Stem Cell Transplantations: A Study of the Incidence, Risk Factors, and Clinical Outcomes. Acta Haematologica, 2018, 139, 19-27.	1.4	9
209	Acute kidney injury following haplo stem cell transplantation: incidence, risk factors and outcome. Bone Marrow Transplantation, 2018, 53, 483-486.	2.4	11
210	Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the <scp>TNFAIP</scp> 3/ <scp>NF</scp> â€₽B/ <scp>SMAD</scp> pathway in patients with immune thrombocytopenia. British Journal of Haematology, 2018, 180, 395-411.	2.5	32
211	Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2018, 53, 507-510.	2.4	4
212	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 600-608.	2.4	9
213	The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2018, 97, 1547-1554.	1.8	15
214	lgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. Annals of Hematology, 2018, 97, 1399-1406.	1.8	6
215	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1936-1943.	2.0	25
216	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clinical Immunology, 2018, 190, 32-40.	3.2	24

#	Article	IF	CITATIONS
217	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. Science China Life Sciences, 2018, 61, 924-933.	4.9	1
218	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. Annals of Hematology, 2018, 97, 1209-1217.	1.8	10
219	Monitoring of postâ€transplant <i><scp>CBFB</scp>â€<scp>MYH</scp>11</i> as minimal residual disease, rather than <i><scp>KIT</scp></i> mutations, can predict relapseÂafter allogeneic haematopoietic cell transplantation inÂadults with inv(16) acute myeloid leukaemia. British Journal of Haematology, 2018, 180. 448-451.	2.5	26
220	Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 163-168.	2.0	6
221	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 741-750.	2.0	36
222	Thrombotic microangiopathy with concomitant <scp>GI</scp> aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. European Journal of Haematology, 2018, 100, 171-181.	2.2	13
223	Utility of flexible bronchoscopy with polymerase chain reaction in the diagnosis and management of pulmonary infiltrates in allogeneic <scp>HSCT</scp> patients. Clinical Transplantation, 2018, 32, e13146.	1.6	8
224	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chinese Medical Journal, 2018, 131, 2808-2816.	2.3	7
225	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. Chinese Medical Journal, 2018, 131, 2185-2192.	2.3	5
226	Dendritic Cells Are Critical for the Activation and Expansion of Vδ2+ T Cells After Allogeneic Hematopoietic Transplantation. Frontiers in Immunology, 2018, 9, 2528.	4.8	10
227	Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. Clinical Infectious Diseases, 2018, 67, S162-S173.	5.8	36
228	Endothelial nitric oxide synthase enhancer AVE3085 reverses endothelial dysfunction induced by homocysteine in human internal mammary arteries. Nitric Oxide - Biology and Chemistry, 2018, 81, 21-27.	2.7	12
229	Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. Oncologist, 2018, 23, 1349-1357.	3.7	17
230	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Letters, 2018, 438, 63-75.	7.2	116
231	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Science Bulletin, 2018, 63, 1376-1382.	9.0	27
232	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1866-1872.	2.0	1
233	An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2018, 182, 679-692.	2.5	36
234	Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1981-1989.	2.0	26

#	Article	IF	CITATIONS
235	Evaluation of glucocorticoid compared with immunoglobulin therapy of severe immune thrombocytopenia during pregnancy: Response rate and complication. American Journal of Reproductive Immunology, 2018, 80, e13000.	1.2	9
236	Impairment of bone marrow endothelial progenitor cells in acute graftâ€versusâ€host disease patients after allotransplant. British Journal of Haematology, 2018, 182, 870-886.	2.5	15
237	Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. Bone Marrow Transplantation, 2018, 53, 770-773.	2.4	18
238	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer Journal, 2018, 8, 76.	6.2	21
239	Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China. Medical Science Monitor, 2018, 24, 5258-5270.	1.1	2
240	Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course. Blood, 2018, 132, 5734-5734.	1.4	0
241	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Blood, 2018, 132, 3463-3463.	1.4	0
242	Haplo-SCT Mediates Stronger GVL Effect Than HLA-Matched Sibling Allograft By Significantly Reducing Leukemia Burden. Blood, 2018, 132, 2186-2186.	1.4	0
243	Osteoclast Stimulatory Transmembrane Protein (OCSTAMP) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma. Blood, 2018, 132, 5264-5264.	1.4	0
244	Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?. Blood, 2018, 132, 2813-2813.	1.4	0
245	Poor NKG2C+ Adaptive NK Cell Recovery at Early Stage after Allo-HSCT Increased the Occurrence of Refractory Cytomegalovirus Infection. Blood, 2018, 132, 360-360.	1.4	Ο
246	Association between C-reactive protein levels in the first 1–3 days post-transplant and allogeneic immune reactions. Biomarkers in Medicine, 2017, 11, 117-124.	1.4	1
247	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 44.	17.0	51
248	Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. Journal of Hematology and Oncology, 2017, 10, 25.	17.0	151
249	Viral encephalitis after haploâ€identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. European Journal of Haematology, 2017, 98, 450-458.	2.2	22
250	Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1311-1319.	2.0	66
251	IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. Biology of Blood and Marrow Transplantation, 2017, 23, 1303-1310.	2.0	40
252	Recipientâ€donor KIR ligand matching prevents CMV reactivation postâ€haploidentical T cellâ€replete transplantation. British Journal of Haematology, 2017, 177, 766-781.	2.5	21

#	Article	IF	CITATIONS
253	A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 1158-1164.	2.0	8
254	Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Journal of Translational Medicine, 2017, 15, 57.	4.4	32
255	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 829-838.	1.8	39
256	Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 906-912.	2.0	25
257	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Longâ€ŧerm outcomes of a prospective randomized trial. Cancer, 2017, 123, 2881-2892.	4.1	63
258	Donorâ€derived <scp>CD</scp> 19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2017, 179, 598-605.	2.5	87
259	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. Oncolmmunology, 2017, 6, e1356152.	4.6	28
260	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells and Development, 2017, 26, 1648-1661.	2.1	36
261	Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus. Journal of Infectious Diseases, 2017, 216, 945-956.	4.0	82
262	Evaluation of the new Chinese Disseminated Intravascular Coagulation Scoring System in critically ill patients: A multicenter prospective study. Scientific Reports, 2017, 7, 9057.	3.3	17
263	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematology,the, 2017, 4, e487-e496.	4.6	38
264	Effects of pre―and postâ€ŧransplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigenâ€matched or mismatched related donor allografts. American Journal of Hematology, 2017, 92, E659-E661.	4.1	19
265	Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China. Clinical Therapeutics, 2017, 39, 1758-1768.	2.5	2
266	Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leukemia Research, 2017, 59, 136-141.	0.8	8
267	The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leukemia and Lymphoma, 2017, 58, 1135-1143.	1.3	27
268	Multicentre, randomised phase <scp>III</scp> study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. British Journal of Haematology, 2017, 176, 101-110.	2.5	55
269	Endothelial progenitor cells improve the quality of transplanted hematopoietic stem cells and maintain longer term effects in mice. Annals of Hematology, 2017, 96, 107-114.	1.8	3
270	Higher dose of <scp>CD</scp> 34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. Clinical Transplantation, 2017, 31, e12880.	1.6	4

#	Article	IF	CITATIONS
271	Risk factors for herpes simplex virus-1/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation. Journal of Clinical Virology, 2017, 95, 20-25.	3.1	10
272	Inflammation-Related Gene Polymorphisms Associated With Primary Immune Thrombocytopenia. Frontiers in Immunology, 2017, 8, 744.	4.8	32
273	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Journal of Hematology and Oncology, 2017, 10, 134.	17.0	132
274	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 2143-2150.	2.0	19
275	Cysteine and glycine-rich protein 2 (<i>CSRP2</i>) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. Oncotarget, 2017, 8, 35984-36000.	1.8	23
276	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. Journal of Thoracic Disease, 2016, 8, 2219-2225.	1.4	2
277	Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clinical Transplantation, 2016, 30, 994-1001.	1.6	11
278	Haploidentical hematopoietic stem cell transplantation for paediatric highâ€risk <scp>T</scp> â€cell acute lymphoblastic leukaemia. Pediatric Transplantation, 2016, 20, 572-580.	1.0	8
279	Salvage chemotherapy followed by granulocyte colonyâ€stimulating factorâ€primed donor leukocyte infusion with graftâ€vs.â€host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. European lournal of Haematology. 2016. 96. 297-308.	2.2	37
280	High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. European Journal of Haematology, 2016, 96, 517-526.	2.2	8
281	Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood, 2016, 128, 2988-2999.	1.4	73
282	Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1080-1086.	2.0	16
283	High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 144, 6-11.	1.7	5
284	Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clinical Cancer Research, 2016, 22, 3467-3476.	7.0	142
285	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. Journal of Clinical Oncology, 2016, 34, 1855-1863.	1.6	100
286	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. Biology of Blood and Marrow Transplantation, 2016, 22, 2235-2242.	2.0	11
287	Factors affecting the CD34+ cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor. Transfusion and Apheresis Science, 2016, 55, 311-317.	1.0	2
288	Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. Stem Cells Translational Medicine, 2016, 5, 1631-1643.	3.3	57

#	Article	IF	CITATIONS
289	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1637-1643.	1.8	27
290	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. Oncolmmunology, 2016, 5, e1250992.	4.6	21
291	Minimal residual disease- and graft-vshost disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. Journal of Hematology and Oncology, 2016, 9, 87.	17.0	57
292	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. Journal of Infection, 2016, 73, 261-270.	3.3	19
293	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with highâ€risk acute lymphoblastic leukemia. International Journal of Cancer, 2016, 139, 2106-2115.	5.1	47
294	Haploâ€identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. British Journal of Haematology, 2016, 175, 265-274.	2.5	109
295	Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. Oncolmmunology, 2016. 5. e1242546.	4.6	11
296	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chinese Journal of Cancer, 2016, 35, 46.	4.9	11
297	Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1233-1240.	1.8	16
298	Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1376-1382.	2.0	33
299	Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. Leukemia Research, 2016, 47, 8-15.	0.8	7
300	Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer, 2016, 16, 269.	2.6	31
301	Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution. Clinical Transplantation, 2016, 30, 170-178.	1.6	11
302	Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3K–AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 139, 1-9.	1.7	8
303	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	1.3	8
304	Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. Journal of Clinical Virology, 2016, 75, 10-15.	3.1	21
305	<i>Helicobacter pylori</i> infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets, 2016, 27, 223-229.	2.3	7
306	Aberrant TNFAIP3 Induces Mesenchymal Stem Cell Impairment Via the NF-Kb/SMAD7 Signaling Pathway in Immune Thrombocytopenia. Blood, 2016, 128, 364-364.	1.4	1

#	Article	IF	CITATIONS
307	Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget, 2016, 7, 30892-30906.	1.8	48
308	The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5800-5800.	1.4	0
309	Haploidentical Stem Cell Transplantation for Rare Pediatric Diseases at Peking University People's Hospital. Blood, 2016, 128, 5848-5848.	1.4	Ο
310	Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 4602-4602.	1.4	0
311	Desialylation of Megakaryocytes Diminishes Platelet Production By Disrupting Megakaryocyte Adhesion, Migration and Proplatelet Formation in Chronic Immune Thrombocytopenia. Blood, 2016, 128, 165-165.	1.4	0
312	ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study. Blood, 2016, 128, 2902-2902.	1.4	0
313	Crucial Role of Complement Activation and IL-1Î ² in Bone Marrow Niche of Immune Thrombocytopenia. Blood, 2016, 128, 166-166.	1.4	Ο
314	Optimal Dose of Antithymocyte Globulin in Conditioning Regimens for Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: Long-Term Outcomes of a Prospective Randomised Trial. Blood, 2016, 128, 3433-3433.	1.4	1
315	Association Between C-Reactive Protein in the First 1-3 Days Post-Transplant and Allogeneic Immune Reactions in Pediatric Haploidentical Stem Cell Transplantation. Blood, 2016, 128, 5794-5794.	1.4	Ο
316	Dysfunction of Bone Marrow Endothelial Progenitor Cells from Subjects with Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation Can be Improved By Atorvastatin. Blood, 2016, 128, 3386-3386.	1.4	0
317	Haploidentical stem cell transplantation in patients aged 50Âyr and older with leukemia: similar outcomes compared to younger adults. Clinical Transplantation, 2015, 29, 523-530.	1.6	14
318	Infusionâ€related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graftâ€versusâ€host disease. Pediatric Transplantation, 2015, 19, 918-924.	1.0	11
319	Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. Journal of Translational Medicine, 2015, 13, 391.	4.4	24
320	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. Journal of Hematology and Oncology, 2015, 8, 116.	17.0	34
321	Recipient expression of ligands for donor inhibitory KIRs enhances NKâ€cell function to control leukemic relapse after haploidentical transplantation. European Journal of Immunology, 2015, 45, 2396-2408.	2.9	42
322	Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. Transfusion, 2015, 55, 2023-2031.	1.6	16
323	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte–colonyâ€stimulating factor–mobilized marrow harvests and peripheral blood harvests. Transfusion, 2015, 55, 2874-2881.	1.6	18
324	Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2015, 94, 837-845.	1.8	6

#	Article	IF	CITATIONS
325	Recruitment of CD8+ T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1+ in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2015, 94, 1689-1698.	1.8	15
326	The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Annals of Hematology, 2015, 94, 1699-1705.	1.8	77
327	Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study. Thrombosis Research, 2015, 135, 835-840.	1.7	3
328	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood, 2015, 125, 3956-3962.	1.4	387
329	Haploidentical Hematopoietic Stem Cell Transplantation without InÂVitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1110-1116.	2.0	44
330	Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter Prospective Observational Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1117-1126.	2.0	81
331	ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia. Leukemia Research, 2015, 39, 1229-1238.	0.8	15
332	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leukemia and Lymphoma, 2015, 56, 3116-3123.	1.3	31
333	IL-35 inhibits acute graft-versus-host disease in a mouse model. International Immunopharmacology, 2015, 29, 383-392.	3.8	11
334	Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2015, 21, 2185-2191.	2.0	46
335	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology and Oncology, 2015, 8, 84.	17.0	160
336	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphiaâ€negative acute lymphoblastic leukemia: No difference in the high―and lowâ€risk groups. International Journal of Cancer, 2015, 136, 1697-1707.	5.1	42
337	Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors. Blood, 2015, 126, 62-62.	1.4	1
338	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Might Overcome the Adverse Effect of Minimal Residue Disease Pretransplant in Patients with Standard-Risk Acute Myeloid Leukemia. Blood, 2015, 126, 1970-1970.	1.4	0
339	Association between an Impaired Bone Marrow Vascular Microenvironment and Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1190-1197.	2.0	49
340	Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cell–Replete Haploidentical Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1176-1182.	2.0	21
341	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1314-1321.	2.0	36
342	Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2014, 20, 2023-2028.	2.0	25

#	Article	IF	CITATIONS
343	Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 2014, 124, 843-850.	1.4	285
344	IL-35 and Rapamycin Reduce Acute Graft-Versus-Host Disease Associated with Decreased Platelet Aggregation in a Mouse Model. Blood, 2014, 124, 3814-3814.	1.4	1
345	Hepatocyte Growth Factor Gene-Modified Adipose-Derived Mesenchymal Stem Cells Ameliorate Radiation Induced Liver Damage in a Rat Model. PLoS ONE, 2014, 9, e114670.	2.5	49
346	PDGFR-Mediated Cytomegalovirus Infection of Megakaryocytes Induces Thrombocytopenia Via Demethylation of AML1 and IEX-1 in the TPO/c-Mpl Signaling Pathway Following Allo-HSCT. Blood, 2014, 124, 3937-3937.	1.4	0
347	Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study. Blood, 2014, 124, 2778-2778.	1.4	0
348	Adipose-Derived Mesenchymal Stem Cells with Potential to Ameliorate Platelet Recovery and Enhance Megakaryopoiesis in a Mouse Model of Radiation-Induced Thrombocytopenia Via the PI3k/Akt Pathway. Blood, 2014, 124, 2931-2931.	1.4	0
349	Desialylation Induces Apoptosis and Phagocytosis of Platelets in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 432-432.	1.4	0
350	Reduced IL-35 Levels Are Associated with Increased Platelet Aggregation and Activation in Patients with Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 1174-1174.	1.4	51
351	Interferon Î \pm : the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion. Chinese Medical Journal, 2014, 127, 2583-7.	2.3	14
352	Negative association of donor age with CD34â ² cell dose in mixture allografts of C-CSF-primed bone marrow and C-CSF-mobilized peripheral blood harvests. Chinese Medical Journal, 2014, 127, 3597-601.	2.3	6
353	Longâ€ŧerm followâ€up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer, 2013, 119, 978-985.	4.1	224
354	Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway. Leukemia Research, 2013, 37, 1719-1725.	0.8	11
355	Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates. Clinical Transplantation, 2013, 27, 80-89.	1.6	18
356	Nonmalignant Late Effects in Survivors of Partially Matched Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 777-783.	2.0	10
357	High-Dose Cyclophosphamide Therapy Associated with Diffuse Alveolar Hemorrhage after Allogeneic Hematopoietic Stem Cell Transplantation. Respiration, 2013, 86, 453-461.	2.6	9
358	Hybrid Bayesian inference on HIV viral dynamic models. Journal of Applied Statistics, 2013, 40, 2516-2532.	1.3	2
359	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood, 2013, 121, 4056-4062.	1.4	277
360	Intracranial Hemorrhage and Mortality In 1461 Patients After Allogeneic Hematopoietic Stem Cell Transplantation For 6-Year Follow-Up: Study Of 44 Cases. Blood, 2013, 122, 3322-3322.	1.4	12

#	Article	IF	CITATIONS
361	Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia. Blood, 2013, 122, 1346-1346.	1.4	0
362	Increased ADAM28 Levels In PlasmaÂand Bone Marrow CellsÂof Patients With Adult Acute Leukemia. Blood, 2013, 122, 4990-4990.	1.4	0
363	Idiopathic inflammatory demyelinating diseases of the central nervous system in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors and survival. Chinese Medical Journal, 2013, 126, 1096-102.	2.3	6
364	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood, 2012, 119, 5584-5590.	1.4	107
365	The effect of HLA disparity on clinical outcome after HLAâ€haploidentical blood and marrow transplantation. Clinical Transplantation, 2012, 26, 284-291.	1.6	39
366	A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation. Blood, 2012, 120, 4512-4512.	1.4	0
367	Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial. Blood, 2012, 120, 139-139.	1.4	1
368	Allo-hematopoietic stem cell transplantation is a potential treatment for a patient with a combined disorder of hereditary spherocytosis. Chinese Medical Journal, 2012, 125, 947-50.	2.3	2
369	Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with a Reduction in Ploidy and an Immaturation of Megakaryocytes. Biology of Blood and Marrow Transplantation, 2011, 17, 274-280.	2.0	46
370	Simulating energy efficient wireless sensor networks using cellular automata. , 2011, , .		4
371	Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory Cytokines. Biology of Blood and Marrow Transplantation, 2010, 16, 1567-1575.	2.0	28
372	Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up. Blood, 2010, 116, 2347-2347.	1.4	0
373	Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Association with Reduced Ploidy and Immaturation of Megakaryocytes. Blood, 2010, 116, 4695-4695.	1.4	Ο
374	Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children. Biology of Blood and Marrow Transplantation, 2009, 15, 91-94.	2.0	28
375	Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 257-265.	2.0	278
376	Platelet Engraftment in Patients with Hematologic Malignancies following Unmanipulated Haploidentical Blood and Marrow Transplantation: Effects of CD34+ Cell Dose and Disease Status. Biology of Blood and Marrow Transplantation, 2009, 15, 632-638.	2.0	63
377	Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable to Unrelated Donor Transplantation for Patients with Hematologic Malignancies Blood, 2009, 114, 1197-1197.	1.4	0
378	Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Chinese Medical Journal, 2007, 120, 463-8.	2.3	1

#	Article	IF	CITATIONS
379	HLA Mismatched/Haploidentical Haematopoietic Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia Blood, 2006, 108, 3154-3154.	1.4	0
380	Early detection of cognitive impairment in patients with obstructive sleep apnea syndrome: an event-related potential study. Neuroscience Letters, 2002, 325, 99-102.	2.1	32
381	Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 0, 13, .	4.8	3
382	Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study. Blood Advances, 0, , .	5.2	1
383	Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. Frontiers in Immunology, 0, 13, .	4.8	3